Welcome to our dedicated page for Alterity Therapeutics news (Ticker: ATHE), a resource for investors and traders seeking the latest updates and insights on Alterity Therapeutics stock.
Alterity Therapeutics Limited develops treatments for neurodegenerative diseases, with a clinical program centered on Multiple System Atrophy and related Parkinsonian disorders. News about ATHE commonly covers ATH434, its lead MSA candidate, Phase 2 analyses, FDA interactions, chemistry, manufacturing and control updates, and presentations at neurology and imaging conferences.
Coverage also includes bioMUSE Natural History Study biomarker work, including quantitative susceptibility mapping MRI for iron dysregulation in MSA, Appendix 4C cash flow and corporate updates, board appointments, and discussions of the company’s drug discovery platform for patentable chemical compounds targeting neurological disease pathology.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced a successful pre-IND meeting with the FDA regarding its lead compound, ATH434, for treating Multiple System Atrophy (MSA). Following a Phase 1 clinical trial, the FDA provided guidance on the Phase 2 study design, including safety monitoring and patient population. Importantly, there are no approved treatments for MSA, prompting collaboration with the FDA to establish appropriate efficacy endpoints. The company will also conduct a natural history study called bioMUSE to better track disease progression.